CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Niraparib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04409002
NCT04409002Phase 2Completed
CompareCT.gov

A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer

Massachusetts General Hospital·interventional·Posted Jun 1, 2020·Updated Aug 15, 2025

In Brief

A Phase 2 clinical trial evaluating Niraparib, Dostarlimab, and 1 other intervention for Pancreatic Cancer and Metastatic Pancreatic Cancer. Completed, enrolled 18 participants across 1 site.

Detailed Summary

This research is being done to see how the combination of dostarlimab, niraparib, and radiation therapy works in controlling metastatic pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer, Metastatic Pancreatic Cancer
CountriesUnited States
CollaboratorsTesaro, Inc.

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJun 1, 2020
Enrollment StartJul 23, 2020
Primary CompletionJan 19, 2022
Study CompletionFeb 25, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.1 years ago

Interventions

Niraparibdrug

Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment

Dostarlimabdrug

Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study

Radiationradiation

Radiation therapy on every other week day of cycle 2 only. Radiation will begin on Cycle 2 Day 1